| Literature DB >> 32908828 |
Abu Baker Sheikh1, Abhilash Perisetti2, Nismat Javed3, Rahul Shekhar1.
Abstract
Eribulin is an antineoplastic agent used in advanced breast cancer refractory to anthracycline and taxane treatment regimens. A wide variety of side effects with unclear mechanisms have been noted, but encephalopathy has not been widely reported. Here we describe the case of a middle-aged woman treated with eribulin for advanced breast cancer who subsequently developed central nervous system drug-induced toxicity but improved promptly with steroid administration. LEARNING POINTS: Eribulin-induced encephalopathy is a diagnosis of exclusion and should be included in the differential diagnosis of patients treated with eribulin and presenting with altered mental status.Eribulin can cross the blood-brain barrier.Steroids and drug cessation should be the mainstay of treatment in cases of eribulin-induced encephalopathy. © EFIM 2020.Entities:
Keywords: Eribulin; breast cancer; encephalopathy
Year: 2020 PMID: 32908828 PMCID: PMC7473676 DOI: 10.12890/2020_001708
Source DB: PubMed Journal: Eur J Case Rep Intern Med ISSN: 2284-2594